Erlotinib monotherapy in patients with advanced non-small cell lung cancer: An effective approach with low toxicity

Anticancer Research

Volumn 28, Issue 4 C, 2008, Pages 2409-2415

  Ardavanis, Alexandros ^a   Koumna, Stella ^a   Fragos, Ioannis ^a   Malliou, Savvoula ^a   Kyriakou, Flora ^a   Mantzaris, Ioannis ^a   Scorilas, Andreas ^b   Rigatos, Gerassimos ^a  

^a SAINT SAVVAS HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Advanced non small cell lung cancer; Erlotinib; Monotherapy

Indexed keywords

ERLOTINIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE CONTROL; DISEASE DURATION; DISEASE FREE SURVIVAL; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; METASTASIS; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; RASH; RECURRENT CANCER; RETROSPECTIVE STUDY; SEX RATIO; SURVIVAL TIME; UNDIFFERENTIATED CARCINOMA;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RETROSPECTIVE STUDIES;

EID: 48849110458     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Haura EB: Treatment of advanced non-small cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies. Cancer Control 8(4): 326-336, 2001.
2. Maione P, Gridelli C, Troiani T and Ciardiello F: Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC. Oncologist 11(3): 274-284, 2006.
3. Mountain CF: The international system for staging lung cancer. Semin Surg Oncol 18(2): 106-115, 2000.
4. Cascone T, Gridelli C and Ciardiello F: Combined targeted therapies in non-small cell lung cancer: a winner strategy? Curr Opin Oncol 19(2): 98-102, 2007.
5. Gridelli C, Rossi A and Maione P: Treatment of non-small cell lung cancer: state of the art and development of new biologic agents. Oncogene 22(42): 6629-6638, 2003.
6. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT and Somerfield MR: American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22(2): 330-353, 2004.
7. Bunn PA Jr and Kelly K: New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 4(5): 1087-1100, 1998.
8. Giaccone G: Targeting HER1/EGFR in cancer therapy: experience with erlotinib. Future Oncol 1(4): 449-460, 2005.
9. Waters JS and O'Brien ME: The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE). Br J Cancer 87(5): 481-490, 2002.
10. von Eyben FE: Epidermal growth factor receptor inhibition and non-small cell lung cancer. Crit Rev Clin Lab Sci 43(4): 291-323, 2006.
11. Normanno N, Bianco C, De Luca A, Maiello MR and Salomon DS: Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 10(1): 1-21, 2003.
12. Kurie JM, Shin HJ, Lee JS, Morice RC, Ro JY, Lippman SM, Hittelman WN, Yu R, Lee JJ and Hong WK: Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin Cancer Res 2(10): 1787-1793, 1996.
13. Arteaga CL: ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res 284(1): 122-130, 2003.
14. Bedano PM and Hanna NH: Salvage therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 1(6): 582-587, 2006.
15. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP and Baselga J: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21(12): 2237-2246, 2003.
16. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ and Kay AC: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290(16): 2149-2158, 2003.
17. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, Milanowski J, Karnicka-Mlodkowski H, Pesek M, Serwatowski P, Ramlau R, Janaskova T, Vansteenkiste J, Strausz J, Manikhas GM and Von Pawel J: Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25(12): 1545-1552, 2007.
18. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A and Johnson DH: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 22(5): 777-784, 2004.
19. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A and Johnson DH: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 22(5): 785-794, 2004.
20. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH and Miller VA: TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer. J Clin Oncol 23(25): 5892-5899, 2005.
21. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P and Seymour L: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353(2): 123-132, 2005.
22. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6): 649-655, 1982.
23. Travis WD CT, Corrin B et al: World Health Organization: Histological Typing of Lung and Pleural Tumours (3rd Edn). Berlin, Germany: Springer-Verlag, 1999.
24. Park JO, Lee SI, Song SY, Kim K, Kim WS, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Lee KS and Park K: Measuring response in solid tumors: comparison of RECIST and WHO response criteria. Jpn J Clin Oncol 33(10): 533-537, 2003.
25. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
26. Peto R and Peto J: Asymptotically efficient rank invariant test procedures. J Stat Soc (Series A) 135: 185-198, 1972.
27. Cox DR: Regression models in life tables (with discussion). J R Stat Soc B 34: 187-220, 1972.
28. Eberhard DA, Giaccone G and Johnson BE: Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 26(6): 983-994, 2008.
29. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F and Hammershaimb L: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18(12): 2354-2362, 2000.
30. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L and Bunn PA Jr: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 22(9): 1589-1597, 2004.
31. Ramalingam S and Sandler AB: Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection. Oncologist 11(6): 655-665, 2006.
32. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y and Berille J: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18(10): 2095-2103, 2000.
33. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, da Cunha Santos G, Lagarde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J and Shepherd FA: Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 353(2): 133-144, 2005.